Hanmi Pharm secures Asia and Africa distribution rights for 'Rolbedon'

Hanmi Pharm secures the Asian and African distribution rights for 'Rolvedon' (domestic name Rollontis), a bio new drug for treating neutropenia, a side effect of cancer treatment.

Hanmi Pharmaceutical's new drug for neutropenia treatment, 'Rolontis' (export name Rolbedon)
[Photo by Hanmi Pharmaceutical]

Hanmi Pharm announced, "On the 1st, we reached an agreement to slightly adjust the sales rights in certain regions of Rolvedon's global distribution rights, which were held by our partner, Ascelto." Ascelto had acquired Spectrum, Hanmi Pharm's long-time partner, last year, and held exclusive global rights to Rolvedon worldwide except for Korea, China, and Japan. During the acquisition process, Hanmi Pharm acquired a 2.36% stake in Ascelto.

A Hanmi Pharm official explained the agreement as "an effort to further strengthen the partnership with our partner and secure a successful global sales strategy for Rolvedon." Following this adjustment of distribution rights, Ascelto plans to focus on enhancing Rolvedon's value in the U.S. market, while Hanmi Pharm aims to explore potential opportunities in the Asian and African regions.

This content was produced with the assistance of AI translation services.